Evidence O
that O
endogenous B-gene
gamma I-gene
interferon I-gene
is O
produced O
early O
in O
Listeria B-species
monocytogenes I-species
infection I-disease
. O

It O
has O
been O
presumed O
that O
gamma B-gene
interferon I-gene
( O
IFN B-gene
- I-gene
gamma I-gene
) O
, O
which O
plays O
an O
essential O
role O
in O
antilisterial O
resistance O
, O
is O
produced O
late O
in O
Listeria B-species
monocytogenes I-species
infection I-disease
. O

In O
the O
present O
study O
, O
however O
, O
IFN B-gene
- I-gene
gamma I-gene
was O
detected O
in O
the O
bloodstreams O
and O
spleens O
of O
mice B-species
from O
days O
1 O
to O
4 O
of O
L. B-species
monocytogenes I-species
infection O
by O
both O
a O
double O
- O
sandwich O
enzyme O
- O
linked O
immunosorbent O
assay O
and O
an O
immunohistochemical O
technique O
, O
suggesting O
that O
endogenous O
IFN B-gene
- I-gene
gamma I-gene
is O
produced O
early O
but O
not O
late O
in O
L. O
monocytogenes O
infection O
. O

GN O
- O
I O
machinable O
ceramic O
surfaces O
were O
treated O
with O
37 O
% O
phosphoric B-drug
acid I-drug
for O
30 O
s O
( O
PA O
) O
, O
5 O
% O
hydrofluoric B-drug
acid I-drug
for O
5 O
s O
( O
HF-5 O
) O
, O
10 O
s O
( O
HF-10 O
) O
, O
or O
30 O
s O
( O
HF-30 O
) O
, O
or O
blasting O
with O
50-microm O
Al2O3 B-drug
for O
10 O
s O
( O
AB O
) O
. O

For O
three O
RBSs O
, O
bond O
strength O
at O
TC O
O B-drug
was O
not O
affected O
, O
regardless O
of O
ceramic O
surface O
treatment O
( O
p O
> O
0.05 O
) O
. O

All O
combined O
groups O
of O
ceramic O
surface O
treatment O
and O
resin O
bonding O
system O
decreased O
after O
10,000 O
thermal O
cycles O
, O
especially O
groups O
treated O
with O
alumina B-drug
blasting O
and O
bonded O
with O
each O
of O
three O
RBSs O
( O
p O
< O
0.05 O
) O
. O

Crabmeat O
was O
inoculated O
with O
L. B-species
monocytogenes I-species
V7 O
( O
ca O
. O

10(4 O
) O
CFU O
/ O
g O
) O
and O
incubated O
for O
up O
to O
14 O
days O
at O
5 O
and O
10 O
degrees O
C. O
At O
selected O
incubation O
times O
, O
L. B-species
monocytogenes I-species
was O
removed O
from O
crabmeat O
by O
washing O
with O
0.1 O
M O
potassium B-drug
phosphate I-drug
buffer O
( O
pH O
7.0 O
) O
, O
and O
populations O
were O
determined O
by O
surface O
plating O
on O
LiCl B-drug
- O
phenylethanol B-drug
- O
moxalactam B-drug
agar O
. O

Buffered O
suspensions O
were O
then O
centrifuged O
, O
and O
the O
resulting O
pellets O
were O
suspended O
in O
phosphate B-drug
buffer O
containing O
10 O
% O
glycerol B-drug
and O
stored O
at O
-18 O
degrees O
C. O
Thawed O
, O
diluted O
suspensions O
of O
cells O
were O
tested O
for O
pathogenicity O
by O
intraperitoneal O
injection O
into O
immunocompromised O
and O
nonimmunocompromised O
mice B-species
. O

L. B-species
monocytogenes I-species
cells O
recovered O
from O
crabmeat O
and O
then O
recultured O
in O
tryptose B-drug
phosphate I-drug
broth O
( O
TPB O
) O
, O
as O
well O
as O
cells O
which O
had O
not O
been O
passed O
through O
crabmeat O
but O
had O
been O
cultured O
in O
TPB O
, O
were O
likewise O
harvested O
, O
suspended O
in O
buffered O
10 O
% O
glycerol B-drug
, O
frozen O
, O
thawed O
, O
diluted O
, O
and O
tested O
for O
pathogenicity O
by O
intraperitoneal O
injection O
. O

The O
population O
of O
L. B-species
monocytogenes I-species
necessary O
to O
kill O
about O
50 O
% O
of O
the O
immunocompromised O
mice B-species
in O
each O
test O
set O
within O
7 O
days O
was O
about O
10(4 O
) O
CFU O
, O
and O
this O
result O
was O
not O
significantly O
affected O
by O
storage O
temperature O
of O
the O
crabmeat O
or O
type O
of O
substrate O
, O
i.e. O
, O
crabmeat O
or O
TPB B-drug
, O
on O
which O
it O
had O
grown O
. O

Neonatal O
Alexander B-disease
disease I-disease
: O

Alexander B-disease
disease I-disease
( O
AD B-disease
) O
is O
a O
rare O
neurodegenerative B-disease
disorder I-disease
characterized O
by O
megalencephaly B-disease
, O
leukoencephalopathy B-disease
, O
and O
Rosenthal O
fibers O
within O
astrocytes O
. O

This O
report O
describes O
the O
case O
of O
a O
female O
patient B-species
with O
sonography O
- O
detected O
ventriculomegaly B-disease
at O
32 O
weeks O
' O
gestation O
and O
distinctive O
MR O
imaging O
features O
at O
33 O
and O
36 O
weeks O
' O
gestation O
, O
at O
birth O
, O
and O
at O
2 O
months O
of O
age O
, O
which O
led O
to O
the O
suggested O
diagnosis O
of O
Alexander B-disease
disease I-disease
. O

Molecular O
analysis O
confirmed O
a O
missense O
mutation O
in O
the O
GFAP B-gene
gene I-gene
. O

The O
literature O
contains O
little O
information O
on O
the O
fetal O
MR O
imaging O
findings O
that O
may O
allow O
prenatal O
diagnosis O
of O
AD B-disease
. O

Helicobacter B-species
pylori I-species
treatment O
: O

Clarithromycin B-drug
resistance O
is O
a O
growing O
problem O
in O
many O
countries O
. O

Eradication O
rates O
for O
Helicobacter B-species
pylori I-species
have O
declined O
to O
unacceptable O
levels O
in O
recent O
years O
, O
in O
large O
measure O
because O
of O
clarithromycin B-drug
resistance O
. O

Two O
treatment O
strategies O
( O
quadruple O
therapy O
and O
sequential O
therapy O
) O
are O
emerging O
as O
alternatives O
to O
triple O
therapy O
for O
the O
initial O
treatment O
of O
patients B-species
infected O
with O
H. B-species
pylori I-species
. O

Evidence O
shows O
that O
both O
quadruple O
therapy O
and O
sequential O
therapy O
are O
superior O
to O
triple O
therapy O
in O
patients B-species
with O
resistant O
strains O
of O
H. B-species
pylori I-species
. O

The O
majority O
of O
anesthesia B-disease
services O
provided O
outside O
the O
operating O
room O
or O
ambulatory O
surgery O
center O
is O
in O
the O
office O
- O
based O
setting O
. O

safety O
, O
quality O
of O
care O
and O
patient B-species
satisfaction O
. O

Data O
obtained O
from O
the O
State O
of O
Florida O
office O
- O
based O
surgery O
adverse O
event O
data O
repository O
indicate O
that O
, O
even O
with O
The O
American O
Society O
of O
Anesthesiology O
I O
patients B-species
, O
there O
remains O
opportunity O
to O
improve O
outcomes O
. O

Careful O
patient B-species
selection O
remains O
critical O
, O
especially O
the O
patient B-species
with O
a O
history O
of O
sleep B-disease
apnea I-disease
. O

While O
there O
is O
limited O
office O
- O
based O
anesthesia O
satisfaction O
data O
, O
limiting O
postoperative O
nausea B-disease
and I-disease
vomiting I-disease
remains O
a O
major O
patient B-species
satisfier O
of O
which O
an O
occurrence O
rate O
of O
zero O
may O
be O
possible O
. O

Finally O
, O
with O
advances O
in O
surgical O
technology O
, O
there O
is O
a O
need O
for O
focused O
research O
in O
office O
- O
based O
anesthetic O
techniques O
and O
modalities O
and O
patient B-species
satisfaction O
. O

Wild O
Estonian O
and O
Russian O
sea B-species
trout I-species
( O
Salmo B-species
trutta I-species
) O
in O
Finnish O
coastal O
sea B-species
trout I-species
catches O
: O

The O
threatened O
Estonian O
, O
Finnish O
and O
Russian O
sea B-species
trout I-species
populations O
in O
the O
Gulf O
of O
Finland O
are O
targets O
of O
mixed O
- O
stock O
fisheries O
. O

In O
order O
to O
resolve O
the O
composition O
of O
Finnish O
coastal O
sea B-species
trout I-species
catches O
, O
we O
created O
a O
standardized O
baseline O
dataset O
of O
15 O
DNA O
microsatellite O
loci O
for O
59 O
sea B-species
trout I-species
populations O
around O
the O
Gulf O
of O
Finland O
and O
tested O
its O
resolution O
for O
mixed O
- O
stock O
analysis O
of O
1372 O
captured O
fish O
. O

The O
majority O
( O
76 O
- O
80 O
% O
) O
of O
the O
total O
catch O
originated O
from O
Finnish O
sea B-species
trout I-species
populations O
, O
6 O
- O
9 O
% O
came O
from O
Russian O
and O
12 O
- O
15 O
% O
from O
Estonian O
populations O
. O